Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.…
Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows
Evolus (NASDAQ: EOLS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 365 employees.
The shares were at 6.520 USD on 20 November 2026, down 0.6% over 52 weeks. Its 52-week range is 3.860 USD to 9.310 USD: the price is 30.0% below the high and 68.9% above the low.
Its market capitalisation is 431.55M USD.
Evolus reports return on equity of 223.5%, an operating margin of -5.4% and revenue up 13.0% year over year.
Its debt exceeds its cash by 123.88M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 15.40 USD is 136.2% above the current price. The next earnings report is expected on 2 March 2027.